GlassScriptPhysician profile
John Wb Millspaugh
NPI 1760414429
$4,020.38
in general payments reported to CMS, 2019-2025
30 companies · $791 in 2025
The $791 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $527 · 2021: $208 · 2022: $808 · 2023: $755 · 2024: $199 · 2025: $791.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,744.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,297.25 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $554.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $396.21 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $307.25 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $196.66 | 2022-2023 | Xarelto |
| Lilly USA, LLC | $162.60 | 2019-2025 | Mounjaro, Kisunla |
| Takeda Pharmaceuticals U.S.A., INC. | $152.72 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $104.35 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $99.11 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $96.50 | 2022-2023 | Qelbree |
| Teva Pharmaceuticals USA, INC. | $75.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.58 | 2023-2024 | Trulance, Xifaxan |
| Astellas Pharma US INC | $57.84 | 2024-2025 | Veozah |
| Amgen INC. | $55.94 | 2019-2025 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $52.02 | 2019-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $38.23 | 2022 | |
| Corium, LLC | $34.33 | 2025 | Azstarys |
| Idorsia Pharmaceuticals US INC | $33.95 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $30.77 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $28.70 | 2025 | Rexulti |
| Tolmar, INC. | $25.47 | 2025 | Jatenzo |
| Daiichi Sankyo INC. | $20.85 | 2019 | |
| Xeris Pharmaceuticals, INC. | $20.74 | 2024 | Gvoke Hypopen |
| Corcept Therapeutics | $18.16 | 2025 | Korlym |
| Genentech USA, INC. | $16.89 | 2019 | |
| Glaxosmithkline, LLC. | $16.59 | 2020 | |
| Eisai INC. | $15.86 | 2020 | |
| Exact Sciences Corporation | $15.49 | 2025 | Cologuard Collection Kit |
| Allergan, INC. | $14.62 | 2019 | |
| Antares Pharma, INC. | $11.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Millspaugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.